San Antonio Breast Cancer Symposium 2024 Press Program
UT Health San Antonio and the American Association for Cancer Research (AACR) are co-sponsors of the 2024 San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024, at the Henry B. González Convention Center in San Antonio.
Each year, SABCS features the latest research on the experimental biology, etiology, prevention, diagnosis, and treatment of breast cancer and premalignant breast disease, including data from late-breaking clinical trials. Each year, the symposium attracts thousands of basic researchers, physician-scientists, clinical investigators, breast care providers, and advocates from around the world.
To help reporters plan coverage of the meeting, the SABCS public relations team prepared the following press program.
Press conference 1
SABCS Program Director Kate Lathrop, MD, UT Health San Antonio, moderated the first press conference on Wednesday, December 11.
The following studies were presented:
Next-generation SERD Protects Against Progression in Some Patients With Advanced Breast Cancer Resistant to Standard Hormone Therapy
This study was simultaneously published in the New England Journal of Medicine.
- Presented by Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center
- Presented by Matteo Lambertini, MD, PhD, University of Genova-IRCCS Policlinico San Martino Hospital
- Presented by Judy E. Garber, MD, MPH, Dana-Farber Cancer Institute
Press conference 2
SABCS Codirector Virginia Kaklamani, MD, UT Health San Antonio, moderated the second press conference on Thursday, December 12.
The following studies were presented:
Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients with ‘Good-risk’ DCIS Who Forgo Radiation
- Presented by Jean L. Wright, MD, University of North Carolina, Lineberger Comprehensive Cancer Center
- Presented by Ian Kunkler, MA, MB BChir, University of Edinburgh
COMET Trial Finds Active Monitoring Is a Viable Option for Some Patients With Low-risk DCIS
This study was simultaneously published in JAMA.
- Presented by E. Shelley Hwang, MD, MPH, Duke University School of Medicine
LATE-BREAKING ADDITION
The following late-breaking abstract was presented during the press conference:
AFT-38 PATINA: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor-Positive (HR+)/HER2-Positive Metastatic Breast Cancer
- Presented by Otto Metzger, MD, Dana-Farber Cancer Institute
Press conference 3
SABCS Codirector Carlos Arteaga, MD, FAACR, Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, moderated the third and final press conference on Friday, December 13.
The following studies were presented:
- Presented by Nan Chen, MD, University of Chicago Medicine
- Presented by Pedram Razavi, MD, Memorial Sloan Kettering Cancer Center
ZEST Trial Offers Insights for Using ctDNA to Predict Breast Cancer Recurrence
- Presented by Nicholas Turner, MD, PhD, The Royal Marsden Hospital and Institute of Cancer Research in London
Additional press release
COMET Trial Finds Quality of Life Similar Among Patients with Low-risk DCIS Whether They Received Active Monitoring or Surgery
This study was simultaneously published in JAMA Oncology.
- Presented by Ann Partridge, MD, MPH, Dana-Farber Cancer Institute, Harvard Medical School